News

The MAAs are based on data from the large Phase III TOviTO clinical trial program and further regulatory filings in other countries will be announced in due course.

The company has submitted national marketing authorization variations for Somatuline Autogel 120mg injection to the drug regulatory authorities in 25 countries of the EU. Upon submissions in EU

The company said that total consideration for the product was $12m including an $11m upfront payment and a $1m future milestone payment. ANI intends to launch Lithobid under

The acquisition will allow Encore leverage Quintiles’ breadth and depth of capabilities as well as its global scale to speed up Encore’s vision of improving clinical outcomes through

The company secured a sublicense agreement to manufacture, market and distribute the oral spray product under the brand name TapouT XT in 2013 and since such time has

In 2011, both the firms signed a collaboration and license option agreement for several pre-defined pathogens. As part of the 2011 deal, CureVac met all pre-agreed milestones and

NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena’s lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent

Cortex is developing dronabinol (D9-tetrahydrocannabinol), a cannabinoid, for the treatment of obstructive sleep apnea (OSA), the most common form of sleep apnea. Cortex previously conducted a 21 day,

The combination creates one of the world’s fastest-growing specialty pharmaceutical companies, with annual revenues of more than $15 billion anticipated for 2015. In conjunction with the close of